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Abstract
Rationale Our previous study using memantine in smokers
suggests that there may be a differential role for N-methyl-
D-aspartate (NMDA) receptors in the subjective and
cognitive effects of smoking.
Objectives This study was designed to investigate if D-
cycloserine (DCS) would modulate the subjective and
cognitive effects of limited smoking.
Methods Forty-eight habitual smokers abstinent for a
minimum of 2 h were randomly allocated to receive either
placebo or 50 mg DCS (double-blind) and were subse-
quently required either to smoke half of one cigarette or to
remain abstinent. Subjective and physiological effects of
DCS were measured at baseline, 90 min postcapsule, and
again after the partial-smoking manipulation, while the
effects on sustained attention (rapid visual information
processing test—RVIP) and cognitive flexibility (intra–
extra dimensional set-shift test—IED) were evaluated only
after the partial-smoking manipulation.
Results DCS alone did not produce significant subjective
effects other than an increase in ratings of “Stimulated”. In
combination with partial smoking, however, DCS blocked
the smoking-induced increase in “Stimulated” and the
decrease in “Relaxed” ratings. Furthermore, in combination
with smoking, DCS reduced the number of false alarms
during the RVIP test (an index of inhibitory control) and
produced a small increase in diastolic blood pressure. DCS
failed to modulate IED performance.
Conclusions These findings provide further evidence of a
role for glutamate release in the subjective effects of
smoking but not the effects on attention and cognitive
flexibility. Furthermore, our results indicate that glutamate
release may also be involved in the effect of smoking on
inhibitory control.
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Introduction
Nicotine is known to produce a variety of rewarding
subjective and cognitive effects (Stolerman and Jarvis
1995; Levin et al. 2006). In humans, some of the
measurable subjective effects of nicotine include an
increase in the feelings of “buzzed,” “dizzy,” and “stimu-
lated” (Perkins et al. 1999), while the positive cognitive
effects include improvements in attention (Wesnes and
Warburton 1984) and memory (Rusted et al. 1998; 2005).
The neurobiological mechanisms underlying these actions
of nicotine are complex, involving not only the direct action
of nicotine at receptors for acetylcholine but also changes in
the release of other neurotransmitters, such as dopamine
and glutamate (Watkins et al. 2000). Neurochemical studies
have demonstrated that, at concentrations achieved during
smoking, nicotine can enhance the release and function of
glutamate, through an action at presynaptic receptors (e.g.,
McGehee et al. 1995). Enhanced release can occur in
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several areas of the brain, including in the ventral tegmental
area and the nucleus accumbens (Schilstrom et al. 1998,
2000; Fu et al. 2000; Reid et al. 2000, Mansvelder and
McGehee 2000; Fagen et al. 2003), the prefrontal cortex
(Toth et al. 1993; Gioanni et al. 1999), and the hippocam-
pus (Gray et al. 1996; Radcliffe et al. 1999).
Evidence from behavioral models also indicates a role
for glutamate in the neurobiological mechanisms underly-
ing the actions of nicotine. In rodents, it has been reported
that antagonists acting at N-methyl-D-aspartate (NMDA)
receptor sites can attenuate nicotine self-administration, the
nicotine discriminative stimulus, and nicotine-enhanced
brain reward function (Glick et al. 2001; Blokhina et al.
2005; Zakharova et al. 2005; but see also Wright et al.
2006; Kenny et al. 2009). Receptor sites other than NMDA
may also be involved in these actions of nicotine as the
metabotropic GluR5 antagonist 2-methyl-6-(phenyle-
thynyl)-pyridine (MPEP) has also been reported to be
effective in models of self-administration (Paterson et al.
2003; Paterson and Markou 2005). In studies of the
cognitive effects of nicotine, interactions with glutamatergic
ligands have been reported in tests of working memory and
visual signal detection (Levin et al. 1998; May-Simera and
Levin 2003; Rezvani and Levin 2003), and Quarta et al.
(2007) have recently reported that the competitive NMDA
receptor antagonist (+)3-(2-carboxypiperazin-4-propyl)-1-
propenyl-1-phosphonic acid (CPP) attenuated the ability
of nicotine to improve response accuracy in a five-choice
serial reaction time task. In a spatial navigation task
performed by aged rats, CPP also blocked a beneficial
effect of nicotine on acquisition, while D-cycloserine
enhanced the effect of a subthreshold dose of nicotine
(Riekkinen and Riekkinen 1997). In mice, Ciamei et al.
(2001) showed that the NMDA antagonist dizocilpine could
block the positive effects of nicotine on memory consoli-
dation, at a dose not producing impairment per se.
Few studies have examined the involvement of gluta-
mate in the actions of nicotine or smoking in humans. Knott
et al. (2006) found some evidence for nicotine–glutamate
interactions on both subjective and EEG measures in
volunteers given nicotine gum, although effects varied with
smoking status. Recently, we demonstrated the involvement
of the NMDA receptor in the effects of smoking (Jackson et
al. 2009). In this study, the NMDA antagonist memantine
was effective in blocking the subjective but not the
cognitive enhancing effects of smoking. In contrast, a low
dose (10 mg) of the nicotinic-receptor antagonist mecamyl-
amine reduced the smoking-induced improvement in
attentional performance only. These results suggested that
there is a dissociation in the role of glutamate in the
subjective and cognitive effects of smoking. It has been
argued however that although memantine acts primarily at
the ion channel of the NMDA receptor, during the
physiological release of glutamate, it dissociates rapidly
from the channel, to allow a normal receptor response to
glutamate (Parsons et al. 1999; 2007). As this putative
special action of memantine complicates the interpretation
of results aimed at clarifying the role of glutamate, we
carried out a further investigation, using a different
modulator of NMDA receptor function.
Endogenous glycine acts as a “co-agonist” at a distinct
site on the NMDA receptor, known as the GlycineB site,
and in doing so enhances the action of glutamate.
Although the GlycineB site was once thought to be
saturated in vivo, there is now consensus that it is not
(Danysz and Parsons 1998; Haradahira et al. 2003; Millan
2005), therefore offering the possibility that ligands acting
at this site can modulate the action of glutamate at the
NMDA receptor. D-Cycloserine (DCS) is a partial agonist
that acts at the GlycineB site of the NMDA receptor
(Hood et al. 1989; Priestley et al. 1995) and is believed to
be selective (Millan 2005). As a partial agonist, it acts
firstly to bind to the site and prevent the action of glycine
(i.e., as an antagonist), but with increasing concentration
of the drug, efficacy increases (i.e., an agonist action); at
high concentrations, the efficacy of DCS appears to
diminish (Priestley et al. 1995). In theory then, if
glutamate action at NMDA receptors is involved in the
actions of smoking, a single low dose of DCS would
reduce effects mediated by a high level of endogenous
stimulation at NMDA receptors (via an antagonist action
at the GlycineB site) but potentiate its effects where there
is a lower level of endogenous activity (via an agonist
action at the GlycineB site). We therefore carried out a
study to investigate the effects of DCS on the cognitive
and subjective effects of smoking. We used 50 mg DCS
as a low dose that has previously been reported to be
active in human studies (Ressler et al. 2004; Bailey et al.
2007). In addition, to allow the possible bidirectional
modulation of smoking effects by DCS, we asked
participants to smoke just a portion of a cigarette (partial
smoking) following a period of abstinence. We employed
a similar battery of tests to those used in our previous
study. This included the rapid visual information process-
ing task (RVIP) as a measure of sustained attention,
known to be sensitive to the effects of smoking (Wesnes
and Warburton 1984) and visual analog scales to measure
nicotine- and NMDA-antagonist-related subjective effects
(Jackson et al. 2009). In addition, we extended the battery
to include a test of attentional set-shifting for two
reasons: firstly, we have found in our own studies that
smoking can impair performance on the task (Nesic et al.
2011), and secondly, evidence exists to show that
glutamatergic ligands, including DCS, can modulate
cognitive flexibility in humans (Krystal et al. 1998;
Heresco-Levy et al. 2002). To our knowledge, this was
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the first study to examine the acute effects of DCS in a
population of smokers (previously published in abstract
form, Nesic et al. 2008).
Method
Participants
Forty-eight participants (24 male, 24 female) aged 18–34
(mean 22.7±SEM 0.6) who smoked 5–20 cigarettes per day
(mean 12.5±SEM 0.7) were recruited from the staff and
students at the Universities of Brighton and Sussex and
gave written informed consent to take part in the study.
Individuals who habitually smoked more than 20 cigarettes
per day were not excluded, but none came forward to take
part in the study. The participants were fluent in English,
generally healthy, with no previous history of psychiatric
illness or substance abuse (verified by a medical check),
and were not taking any medication at the time of testing.
The volunteers were dependent smokers, as indicated by
the Fagerström Tolerance Questionnaire (FTQ; Fagerström
1978) score of 5 or above (5–9, mean 5.8±SEM 0.2).
Volunteers were instructed to refrain from smoking for at
least 2 h prior to the testing session (actual range 2–34 h,
mean 8.6±SEM 0.9 h) and were told that compliance
would be verified by administration of a Smokerlyzer test.
They were asked to avoid using illicit drugs for at least
1 week, sleeping pills and other sedatives for 48 h, and
alcohol for 12 h before the testing session. Volunteers were
informed that the purpose of the study was to investigate if
D-cycloserine (DCS) is able to modulate the subjective and
cognitive effects of smoking. They were told that they
would receive a capsule containing either placebo or 50 mg
DCS and that they may be asked to smoke a portion of one
of their own cigarettes during the testing session. At the
start of the testing session volunteers' IQ was assessed
using the National Adult Reading Test (NART).
This study was approved by the Research Ethics
Committees of the University of Sussex and the University
of Brighton. Participants received £25 at the end of the
testing session as compensation for their time.
Experimental design
Volunteers were randomly allocated to one of the four
experimental conditions and tested individually in a
between-subjects 2×2 design, fully balanced for gender,
with the between-subjects factors being drug (placebo—PL
vs. D-cycloserine—DCS) and the partial-smoking condition
(abstinent—NS vs. partial smoking—S). In order to assess
temporal changes during the course of the experimental
session, “time point” was introduced as a within-subject
factor for some of the dependent variables. Dependent
variables were subjective effects, craving for cigarettes, and
cardiovascular measures (three time points) as well as
sustained attentional performance (one time point).
Drug treatments
DCS was obtained from a local pharmacy as generic
cycloserine capsules BP (King Pharmaceuticals Ltd,
Donegal, Ireland). Drug and placebo (cornstarch) were
subsequently prepared in opaque, gelatine-free capsules
(Quali-V®, Qualicaps) at the School of Pharmacy and
Biomolecular Sciences, University of Brighton. A dose of
50 mg DCS was chosen for two reasons: Firstly, this dose has
been reported to be active and to have good tolerability in
many previous studies (van Berckel et al. 1997; Ressler et al.
2004; Hofmann et al. 2006; Bailey et al. 2007), and
secondly, in vitro studies indicate that efficacy is lost at
high concentrations (Priestley et al. 1995) and it was unclear
at what dose this might occur in vivo.
Demographic questionnaires
In addition to the FTQ and the questions about the onset
and duration of smoking habit, demographic question-
naires included an Alcohol Use Questionnaire (AUQ;
Mehrabian and Russell 1978) and the Drug Use Ques-
tionnaire (DUQ; Nesic et al. 2011). The AUQ is a self-
report questionnaire that establishes the average weekly
alcohol intake and patterns of drinking behavior over a
6-month period. The DUQ is a self-report questionnaire
that establishes lifetime as well as frequency of current use
of illicit drugs, including amphetamines, cocaine, crack,
MDMA, hallucinogens, opiates, ketamine, gamma-
hydroxy-butyrate (liquid ecstasy), alkyl nitrite inhalants
(poppers), nitrous oxide (laughing gas), and cannabis.
Drugs included in the DUQ are scored as follows: 0=
never used, 1=not used in the last month, 2=used once in
the last month, 3=used 2–5 times in the last month, 4=
used 6–10 times in the last month, 5=used more than 10
times in the last month (with the exception of cannabis,
which is scored as follows: 0=never smoked, 1=not
smoked in the last month, 2=smoked once in the last
month, 3=smoked≤once a week in the last month, 4=
smoked several times a week in the last month, and 5=
smoked every day in the last month). Analysis is
performed on each individual item as well as on the
total drug use score which is obtained by adding up all
the scores for individual drug items. This is an extended
version of a previous DUQ developed in our laboratory
which has been used for drug screening purposes in a
number of studies involving social drinkers (Nesic and
Duka 2006; 2008) and smokers (Nesic et al. 2011).
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Subjective measurements
Visual analog scales A list of nicotine-related subjective
effects (nicotine-VAS) and a list of NMDA antagonist-related
subjective effects (NMDA-VAS) were presented, and volun-
teers were instructed to answer how much each adjective
described how they felt at that moment by placing a mark on
the bipolar visual analog scales (VAS—100 mm) with the
poles “not at all” on the left and “extremely” on the right. The
nicotine-VAS items were “stimulated,” “buzzed,” “impa-
tient,” “alert,” “irritable,” “jittery,” “dizzy,” “relaxed,” and
“hungrier than usual” (Jackson et al. 2009—based on Perkins
et al. 1999). The NMDA-VAS items were “lightheaded,”
“detached,” “forgetful,” “things seem to be moving in slow
motion,” and “unreal” (Jackson et al. 2009).
Questionnaire of Smoking Urges The brief version of
Questionnaire of Smoking Urges (QSU) consists of 10
questions designed to measure desire to smoke and
anticipation of positive outcome (factor 1: positive rein-
forcement) as well as strong urge to smoke and anticipation
of relief of withdrawal (factor 2: negative reinforcement;
Cox et al. 2001). The participants were required to rate how
much each statement applied to them at that particular
moment by writing a mark on a Likert-type seven-point
scale, ranging from “strongly disagree” (1) to “strongly
agree” (7).
Cognitive assessment
RVIP A five-minute RVIP test of sustained attention
(based on Wesnes and Warburton 1984) was administered
using E-Prime 1.1 software and a response box (Psychol-
ogy Software Tools Inc). Volunteers were required to
monitor a continuous stream of digits, presented at a rate
of 80 digits per minute, and to press a response button
whenever they saw either three consecutive odd or three
consecutive even digits. There were eight such target
strings of digits in each one-minute block of the 5-min
test, making a total of 40 targets. The number of correct
targets detections (“hits”) was recorded within a 1,500-ms
window following the onset of the third digit in the target
sequence. The average latency of correct detections and
the number of false alarms (responses to nontargets) were
also recorded. Due to a technical error, RVIP data were
lost for one of the participants in the DCS/S group.
Intra–extra dimensional set-shift test The intra–extra dimen-
sional set-shift test (IED; Cambridge Neuropsychological Test
Automated Battery, Cambridge Cognition) is a computerized
touch-screen test of rule acquisition and reversal, which
begins as a simple visual discrimination task and then
gradually increases in the degree of complexity. The display
features two stimuli in the form of shapes and/or shapes
and lines that appear randomly in two of the four
possible locations on the computer screen. Initially,
volunteers are required to learn a simple discrimination
(i.e., which of the two shapes is correct), then simple
reversal (i.e., change of contingencies, where the previ-
ously incorrect shape becomes correct), and then to
attend to the correct shape even when the stimuli become
more complex by the addition of the lines. Subsequently,
a new pair of the compound shape-line stimuli appears,
and volunteers are required to maintain attention to
shapes and to ignore the lines (stage 6—the intradimen-
sional (ID) shift). Finally, in stage 8, another new pair of
compound stimuli appears, and volunteers are now
required to switch their attention to the previously
irrelevant dimension, the lines (the extradimensional
(ED) shift). The main outcome measures derived from
this test are the number of stages completed (1–9), total
number of errors on the test, the number of errors made
on each of the nine blocks, and the total number of
errors prior to the extradimensional shift block. Addi-
tionally two composite outcome measures were analyzed:
attentional flexibility (errors in stages 6+8) and reversal
learning (errors in stages 2+5+7+9).
An associative verbal memory test was also used in this study;
no effects of DCS or partial smoking were observed on
performance of this test, and the results are not reported here.
Experimental procedure
Volunteers reported either to the University of Sussex or
to the University of Brighton Psychopharmacology
Laboratory having been asked to abstain from smoking
for at least 2 h. They first completed a Smokerlyzer test
measuring exhaled carbon monoxide (CO) levels in order
to verify compliance with the abstinence requirement. At
the start of the testing session, volunteers performed the
NART after which they were given the opportunity to
familiarize themselves with the RVIP task (20–40-s
practice trial). Following this, they completed Nic-VAS,
NMDA-VAS, and QSU scales (2–3 min), and their blood
pressure was measured using an automatic monitor (time
point: baseline).
Volunteers were then given a capsule which they
swallowed with approximately 100-ml water and waited
for 90 min, during which they completed the demographic
questionnaires. At the end of the waiting period, partic-
ipants' blood pressure was measured again, and they
completed a Smokerlyzer test followed by a test battery
consisting of a 30-min memory test, Nic-VAS, NMDA-
VAS, and QSU (time point: presmoke). After the test
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battery, half of the volunteers were taken to the designated
smoking area and asked to smoke one half of one of their
own cigarettes, while the other half of the volunteers
remained abstinent. The portion of the cigarette to be
smoked was determined individually for each participant by
asking them to indicate the point on their cigarette up to
which they would normally smoke before putting it out,
measuring the length of this portion and then marking a line
halfway along to ensure that they smoked exactly one half
of the amount that they would usually smoke. Upon
returning to the testing room, participants completed
another Smokerlyzer test followed by a test battery
consisting of nicotine-VAS, NMDA-VAS, QSU, RVIP,
IED, and a 10-min memory test, after which their blood
pressure was measured again (time point: postsmoke). At
the end of testing, participants were debriefed about the
purpose of the study, were given £25, and were allowed to
leave the laboratory.
Data analyses
Demographic data, duration of abstinence, baseline breath
CO, and NART scores of the four experimental groups were
analyzed using univariate analysis of variance (ANOVA)
with drug group (PL vs. DCS) and partial-smoking
condition (NS vs. S) as between-subjects factors. The
effects of the drug alone on subjective measures were
evaluated using repeated-measures ANOVA with drug
group as the between-subjects factor and time point
(baseline vs. presmoking) as the within-subjects factor.
Prior to analyzing the effects of the drug and the
partial-smoking manipulation on subjective measures and
breath CO levels, data from the presmoking time point
were analyzed using univariate ANOVAs with drug group
and partial-smoking condition as between-subjects' fac-
tors. Whenever there was a significant interaction of the
two factors at this time point, the postsmoking data for that
variable were converted into percent of change from the
presmoking time point and analyzed using univariate
ANOVA with drug and partial-smoking group as
between-subjects' factors. If the interaction of the two
factors at the presmoking time point was not significant,
these variables were evaluated using repeated-measures
ANOVA with the drug group and the partial-smoking
condition as between-subject factors and time point (pre-
vs. postsmoking) as a within-subject factor. Since the
distribution of response latencies on the RVIP usually
shows positive skewness, natural log transformation was
applied to normalize these data prior to analyses. RVIP
data (response latencies, hits, false alarms) as well as IED
outcome measures were analyzed using univariate
ANOVA, with drug group and partial-smoking condition
as between-subject factors.
All significant interactions were explored using appro-
priate paired and/or unpaired post hoc t tests. We have
decided against applying corrections for multiple compar-
isons as this was a simple 2×2 design (2×2×2 for the
subjective effect variables which were measured before and
after the drug and/or smoking manipulation), and such
corrections are not recommended for exploration of
significant interactions which involves five or less planned
post hoc comparisons (Roberts and Russo 1999).
All statistical analyses were performed using SPSS 15.0.
Results
Population characteristics
The four experimental groups were matched with respect to
age, NART, and smoking habit as well as alcohol and other
drug use (Fs[1,44]<3.60, ps>0.06). Demographic charac-
teristics of the four groups are presented in Table 1. A
main effect of drug group was significant for the number
of hours since the last cigarette, with volunteers allocated
to the DCS group being abstinent for longer than those
in the PL group (means±SEM: PL=6.7±1.0 h, DCS=
10.5±1.5 h; F[1,44]=4.62, p<0.05). Furthermore, a
significant main effect of the smoking group was observed
for the baseline breath CO levels, with participants
allocated to the nonsmoking condition having higher
baseline levels (F[1,44]=4.79, p<0.05; Table 2). In order
to control for the potentially confounding influence of
these differences on the experimental outcome measures,
the number of hours since last cigarette was entered as a
covariate in all subsequent ANOVAs, while the baseline
breath CO level was entered as an additional covariate
only in the analyses of the postsmoking time point
measurements. Only results from the ANCOVAs will be
reported here.
Physiological effects
Effects of DCS during abstinence (baseline vs. presmoke)
The ANCOVA of breath CO levels during abstinence
(baseline vs. presmoking) revealed a main effect of time,
with all participants showing a decline in CO levels
across the two time points (F[1,45]=53.69, p<0.001;
Table 2).
Blood pressure and heart rate remained constant
during abstinence (main effects of time: Fs[1,45]<2.50,
n.s.). DCS did not exert any significant effects on either
systolic or diastolic blood pressure (time×drug interac-
tion: Fs[1,45]<0.84, n.s.), although a main effect of drug
was found for the diastolic blood pressure (F[1,45]=9.71,
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p<0.005; Table 2). Post hoc independent t tests indicated
that the participants in the DCS group had lower diastolic
blood pressure than the PL group at baseline as well as at
the presmoking measurement point (t[46]=2.19, p<0.05
and t[46]=3.66, p<0.001, respectively). No other main
effects or interactions were observed for the blood
pressure and heart rate data (Fs[1,45]<2.85, n.s.). Blood
pressure and heart rate data are presented in Table 2.
Effects of DCS in combination with partial smoking
(presmoke vs. postsmoke)
Repeated ANCOVA of the CO levels before and after the
partial-smoking manipulation in the entire experimental
sample revealed a significant two-way interaction of partial-
smoking condition and time point (F[1,42]=34.50,
p<0.001; Table 2). Post hoc t tests revealed that breath
CO significantly increased in the S condition (t[23]=−5.27,
p<0.001) and declined in the NS condition (t[23]=4.61,
p<0.001). The three-way interaction of drug group, partial-
smoking manipulation, and time point was not significant
(F[1,42]=1.80, n.s.) suggesting that DCS did not alter the
amount of smoke inhaled.
A significant three-way interaction for the diastolic
blood pressure was revealed in the repeated ANCOVA
(time×drug×smoking: F[1,42]=7.56, p<0.01; Table 2).
Post hoc t tests indicated that partial smoking significantly
increased diastolic blood pressure only in the DCS group (t
[11]=−3.01, p<0.05), while a similar increase was not
observed in the PL group (t[11]=0.82, n.s.). The main
effect of drug was again significant (F[1,42]=9.51,
p<0.01), although the DCS group no longer had lower
blood pressure than the PL group at the postsmoking
measurement (independent t[41.14]=1.80, n.s.). Indepen-
dently of the drug manipulation, partial smoking also
induced a significant increase in systolic blood pressure
(t[23]=−2.51, p<0.05) which was not seen in the abstinent
group (t[23]=1.288, n.s.; smoking×time point interaction:
F[1,42]=9.81, p<0.005; Table 2). No other main effects or
interactions were observed in the analyses of the blood
pressure and heart rate (Fs[1,42]<2.65, n.s.).
Subjective effects
Effects of DCS during abstinence (baseline vs. presmoke)
Main effects of time point were observed for Nic-VAS
ratings “buzzed,” “impatient,” “dizzy,” “relaxed,” and
“hungrier than usual” and NMDA-VAS ratings of “de-
tached,” “slow motion,” and “unreal” (Fs[1,45]>4.35, ps<
0.05; Table 3 and Fig. 1). All ratings increased significantly
between baseline and presmoking measurements (paired ts
[47]<−2.716, ps<0.01), apart from the “relaxed” ratings,
which tended to decrease (paired t[47]=3.30, p<0.005). In
addition, a significant main effect of time point was
observed for the QSU factor 2 (F[1,45]=7.54, p<0.01;
Table 4), indicating that the negative reinforcement aspect
of craving significantly increased across the two time points
in all participants (paired t[47]=−4.18, p<0.001).
ANCOVA revealed a significant interaction of drug
and time point for the Nic-VAS “stimulated” ratings
(F[1,45]=5.82, p<0.05). Ratings for “stimulated” in-
creased across time in the DCS group (paired t[23]=
−2.823, p<0.01), while this was not observed in the PL
group (t[23]=0.36, n.s.; Fig. 1a). All other subjective
measures remained unaltered by DCS (drug×time inter-
action Fs[1,45]<1.78, n.s.).
Effects of DCS in combination with partial smoking
(presmoke vs. postsmoke)
Univariate ANCOVA of percent change from the presmok-
ing time point was deemed necessary for Nic-VAS
“buzzed,” “jittery,” and “dizzy” ratings, NMDA-VAS
“lightheaded,” “detached,” and “slow motion,” and QSU
factor 2, since the analyses of the presmoking time point
ratings for these dependent variables indicated a drug×
condition interaction (Fs[1,42]>4.36, ps<0.05).
A significant interaction of drug group, partial-smoking
condition, and time point was observed for the Nic-VAS
“stimulated” and “relaxed” ratings (respectively, F[1,42]=
7.50, p<0.01 and F[1,42]=5.18, p<0.05). Partial smoking
induced an increase in “stimulated” and “relaxed” feelings
n=12 per group (6 male, 6 female) DCS/NS DCS/S PL/NS PL/S
Age (years) 24.3 (1.5) 22.4 (1.0) 22.5 (1.2) 21.6 (0.8)
NART score 33.0 (2.5) 28.9 (1.7) 29.0 (2.1) 30.0 (1.3)
Number of cigarettes/day 12.4 (1.7) 11.7 (1.4) 12.1 (1.1) 13.8 (1.8)
FTQ score 5.9 (0.4) 5.3 (0.2) 5.8 (0.2) 6.1 (0.4)
Number of years smoking regularly 8.5 (1.7) 6.3 (0.9) 6.7 (1.0) 5.7 (0.9)
Alcohol use (units/week) 37.2 (6.6) 38.0 (7.5) 27.5 (3.9) 30.0 (4.4)
Drug use (total DUQ score) 8.8 (1.8) 9.6 (1.9) 6.4 (1.2) 6.6 (1.7)
Table 1 Demographic charac-
teristics of the four experimen-
tal groups (DCS = D-cycloserine
condition, PL = placebo condi-
tion, S = partial-smoking condi-
tion, NS = nonsmoking
condition)
Values represent means (±SEM)
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in the PL group (respectively, paired t[11]=−2.45, p<0.05
and t[11]=−2.48, p<0.05). In contrast, in the group given
DCS, ratings for “stimulated” decreased significantly
(t[11]=2.44, p<0.05; Figure 1a), whereas ratings for
“relaxed” remained the same after partial smoking
compared with the presmoking time point (t[11]=−0.27,
n.s.; Figure 1b).
In both treatment groups, partial smoking induced an
increase in Nic-VAS “buzzed” ratings (% change from
presmoking time point, means±SEM: S=175.87±55.28%,
NS=16.17±21.43%; main effect of smoking F[1,42]=4.32,
p<0.05) and a decrease in QSU factor 2 scores (% change
from presmoking time point; main effect of smoking
F[1,42]=8.16, p<0.01; see Table 4). In addition, a
significant interaction of smoking group and time point
was observed in the ANCOVA of QSU factor 1 scores
(F[1,42]=15.90, p<0.001; Table 4), and post hoc tests
revealed that the scores declined after partial smoking
(t[23]=5.06, p<0.001) while they tended to remain un-
changed in the nonsmoking group (t[23]=−0.35, n.s.). DCS
did not modulate the effects of partial smoking either on the
QSU ratings or on the subjective ratings of “buzzed” (main
effect and interaction Fs[1,42]<1.93, n.s.).
Cognitive effects
Effects of DCS in combination with partial smoking
(postsmoke measurement point)
Neither partial smoking nor drug treatment altered the
number of hits occurring during the RVIP test (means±
SEM: DCS/NS=22.8±2.5, DCS/S=25.9±2.2, PL/NS=
27.3±2.5, PL/S=23.4±2.6; main effects and interaction Fs
[1,42]<0.91, n.s.). However, a significant interaction of
drug and partial-smoking condition was revealed for the
number of false alarms (F[1,41]=4.49, p<0.05; Figure 2a).
Partial smoking reduced the number of false alarms in the
DCS group participants, who made significantly less errors
than their nonsmoking counterparts (t[12.91]=2.32,
p<0.05) as well as less errors than the PL group
participants who smoked (t[12.29]=2.17, p=0.05). In
addition, a significant main effect of drug group was
observed for response latencies (F[1,41]=6.43, p<0.05;
Fig. 2b) reflecting the tendency for the participants in the
DCS group to have longer latencies than those in the PL
group (t[45]=−3.04, p<0.005). Partial smoking alone or in
combination with DCS failed to exert a significant effect
on response latencies (main effect and interaction Fs[1,41]
<2.95, n.s.).
None of the aspects of IED test performance appeared to
be influenced either by drug treatment or by partial
smoking (main effects and interactions: Fs[1,42]<3.06,
ps>0.08) apart from the number of errors made in the firstTa
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two reversal blocks which tended to be reduced in the
partial smoking compared to the abstinent condition (main
effect of smoking condition; Block 2 errors: F[1,42]=4.23,
p<0.05; Block 5 errors: F[1,42]=4.02, p=0.052; Table 5).
A nonsignificant trend for partial smoking to improve
IED performance was also observed in the analysis of
total number of errors prior to the extradimensional shift
block (main effect of smoking condition on Blocks 1–7;
F[1,42]=2.98, p=0.053). However, the analysis of this
variable also revealed that duration of abstinence was a
significant determinant of test performance (F[1,42]=
12.38, p<0.001), and post hoc correlational analysis
indicated that longer abstinence was related to greater
number of errors prior to the extradimensional shift
(Pearson's r=0.40, p<0.005).
Discussion
The main findings from this study were that DCS, a partial
agonist at the GlycineB site of the NMDA receptor, given
alone had a mild stimulant effect in abstinent smokers and
slowed reaction times somewhat, during a task of sustained
attention. It reduced the subjective stimulant effect of
partially smoking a cigarette and the accompanying
increase in relaxation. In addition, DCS interacted with
the effect of partial smoking to produce a small increase in
blood pressure. While there was no interaction between
DCS and partial smoking on attentional accuracy, there was
an improvement in inhibitory control. These results fit well
with those of our previous study using the NMDA
antagonist memantine (Jackson et al. 2009) and which
suggested a role for glutamate in subjective response to
smoking, but not in the effects on attentional accuracy. Our
current study also extends those results to reveal the role of
glutamate in inhibitory control.
At the dose of 50 mg DCS used in this study, we
expected to see either “agonist-like” interactions or “antag-
onist-like” interactions with smoking (see “Introduction”
section). A mild stimulant effect was detected using the
Nic-VAS rating scales. Previous studies using this dose of
DCS have not detected this subjective response in healthy
volunteers (van Berckel et al. 1997; D’Souza et al. 2000;
Bailey et al. 2007), although this is the first study to focus
on a population of smokers. It seems unlikely that this
reflects the antagonist property of DCS, as no effects were
detected on the NMDA-VAS rating scales, which we have
previously shown to be sensitive to the effects of the
NMDA antagonist memantine (Jackson et al. 2009). It is
more likely that the stimulant action represents an agonist
property of DCS, and accordingly, this would imply that
glutamate action at NMDA receptors is relatively low in
smokers during early abstinence. Preclinical studies indi-
cate that although the subjective effects of nicotine are
partly mediated by the mesolimbic system, the primary site
of action may be in the prefrontal cortex (Miyata et al.
2002; Smith and Stolerman 2009). Interestingly, NMDA
receptors containing NR2B subunits, for which DCS has
preferential affinity (Priestley et al. 1995), upregulate in the
PFC as a consequence of chronic nicotine self-
administration (Wang et al. 2007). Such an upregulation
could account for the stimulant-like effects of DCS seen in
abstinent smokers in this study, an effect not seen in other
studies employing healthy volunteers.
In addition to its effect on stimulant ratings per se during
abstinence, DCS also interacted with the subjective effects
df=1, 45 DCS PL
t1 t2 t1 t2
Nicotine-VAS
“Buzzed”# 19.3 (4.1) 34.1 (6.3) 22.6 (4.0) 30.6 (5.3)
“Impatient”# 27.1 (5.1) 40.7 (5.5) 30.3 (4.4) 46.5 (4.8)
“Alert” 44.0 (5.1) 46.1 (5.5) 46.2 (4.6) 50.0 (4.5)
“Irritable” 24.5 (4.9) 27.1 (5.3) 31.2 (4.6) 42.0 (5.6)
“Jittery” 21.6 (4.8) 25.5 (5.5) 29.8 (4.4) 34.5 (4.9)
“Dizzy”# 17.0 (4.3) 22.5 (5.4) 17.5 (3.8) 31.2 (5.1)
“Hungrier than usual”# 31.2 (6.4) 38.3 (6.5) 30.8 (5.9) 49.3 (6.7)
NMDA-VAS
“Lightheaded” 26.4 (5.7) 35.9 (6.0) 30.0 (4.8) 40.0 (4.9)
“Detached”# 27.3 (4.7) 37.6 (5.5) 30.7 (4.8) 43.3 (5.2)
“Forgetful” 32.5 (4.5) 42.4 (5.6) 38.9 (4.9) 38.7 (5.6)
“Slow motion”## 16.5 (4.5) 23.5 (5.7) 16.3 (3.2) 26.9 (5.5)
“Unreal”# 16.1 (4.6) 21.4 (5.3) 16.3 (3.8) 23.5 (4.9)
Table 3 Effects of D-cycloser-
ine (DCS) and placebo (PL) on
subjective ratings (nicotine-VAS
and NMDA-VAS items) during
nicotine abstinence
Measurements were taken at
predrug baseline (t1), and
90 min after drug (t2). Values
represent means (±SEM)
# p<0.05; ## p<0.01 (main effect
of time point; t2 vs. t1)
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of partial smoking to reduce the increases seen in relaxed
and stimulant ratings. This effect parallels results seen with
NMDA antagonists in preclinical studies investigating the
stimulus properties of nicotine (Zakharova et al. 2005;
Murray and Bevins, 2007). The result is also consistent
with our previous results showing modulation of smoking-
induced subjective response using the Nic-VAS rating
scales, although the modulated effects differed in that
previously we found evidence for changes in ratings for
“buzzed” (Jackson et al. 2009). One reason for this
difference may be that in the current study, participants
were asked to smoke only a portion of a cigarette, whereas
previously, they smoked a whole cigarette, thus differential
self-dosing produced a different profile of subjective
effects. Different self-dosing is supported by comparison
of the pre–postsmoking change in CO levels of the two
studies (an average increase of 141.1% vs. 43.6% in the
current study). Nevertheless, both studies provide evidence
to support a role for glutamate release underlying subjective
response to smoking. In addition, the “bidirectional action”
of DCS on stimulant ratings depending on whether
participants smoked or were abstinent fits well with the
predicted action of DCS varying according to different
levels of endogenous glutamate activity.
In contrast to the results obtained using the Nic-VAS
rating scales, DCS did not alter craving measured by the
QSU. Both factor 1 craving (positive reinforcement) and
factor 2 craving (negative reinforcement) were reduced
following the partial-smoking manipulation; DCS neither
potentiated nor prevented this effect. Again, these results
are consistent with those of our previous study with
memantine (Jackson et al. 2009) and suggest that
mechanisms other than glutamate activity at NMDA
receptors may be involved in abstinence-related craving.
Interestingly, our results differ from those of Santa Ana et
al. (2009) where following repeated dosing with DCS,
cue-induced (conditioned) craving was attenuated.
Table 4 QSU ratings of the two smoking groups (S = partial-smoking condition, NS = nonsmoking condition) at predrug baseline (t1), before (t2), and
after the partial-smoking manipulation (t3)
QSU factor 1—positive reinforcement QSU factor 2—negative reinforcement
t1 t2 t3*** t1 t2## t3**
DCS/NS 5.3 (0.4) 5.7 (0.4) 5.6 (0.4) 3.2 (0.5) 3.9 (0.6) 3.6 (0.6)
DCS/S 5.5 (0.3) 5.4 (0.4) 4.1 (0.4) 2.8 (0.2) 2.9 (0.4) 2.0 (0.3)
PL/NS 5.3 (0.4) 5.6 (0.4) 5.7 (0.4) 2.6 (0.3) 2.8 (0.3) 3.1 (0.5)
PL/S 5.2 (0.5) 5.6 (0.5) 3.6 (0.5) 3.4 (0.4) 4.3 (0.5) 2.7 (0.3)
The two groups underwent identical protocol until the partial-smoking manipulation, which occurred after t2. Values represent means (±SEM),
minimum score 1, maximum 7
***p<0.001 (smoking group × time point interaction; S: t2<t3, N: t2=t3); **p<0.01 (main effect of smoking group on the t3 scores expressed as
% change from t2); ## p<0.01 (main effect of time point; t2 vs. t1)
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Fig. 1 Effects of drug (DCS) or placebo (PL) on Nic-VAS ratings of a
“Stimulated” and b “Relaxed” at predrug baseline (t1), presmoking
(t2), and postsmoking measurement point (t3). NS nonsmoking group,
S partial-smoking group (the two groups underwent identical protocol
until the partial-smoking manipulation which occurred after t2). ‡p<
0.05, ‡‡p<0.01 (t1 vs. t2; paired t test within DCS group), *p<0.05
(t2 vs. t3; paired t test within PL-S and DCS-S groups)
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DCS lacked any effect on physiological measures, either
alone or in combination with partial smoking, with one
exception. While neither DCS alone nor smoking alone
altered blood pressure, when in combination, a small
increase in diastolic blood pressure was seen. Pressor
responses seen after central administration of nicotinic
agonists have been pharmacologically characterized and
indicate that they are mediated via α7 homomeric nicotinic
receptors (Brezenoff and Giuliano 1982; Buccafusco and
Yang 1993; Li and Buccafusco 2004). As stimulation of α7
homomeric receptors can modulate glutamate release in
several different areas of the brain (Kaiser and Wonnacott
2000; Schilstrom et al. 2000; Jones and Wonnacott 2004;
Livingstone et al. 2009), a reasonable interpretation of our
results is therefore that the increase in diastolic blood
pressure seen following combined DCS and partial smok-
ing was related to the agonist action of DCS potentiating
the action of glutamate at central NMDA receptors. A
candidate area in the brain for this action of DCS is the
ventral portion of the medial prefrontal cortex—firstly
because the prefrontal cortex contains both α7 nicotinic
receptors (Paterson and Nordberg 2000) and NMDA
receptors containing NR2B subunits (Laurie et al. 1997;
Loftis and Janowsky 2003), and secondly, there is evidence
for the involvement of glutamate in ventromedial prefrontal
cortex provoked increases in blood pressure in unanesthe-
tized rats (Resstel and Correa 2006).
DCS had no effect on the number of “hits” (target
detections) achieved during performance of the RVIP test,
either alone or in combination with partial smoking. Partial
Table 5 IED test performance of the four experimental groups (DCS = D-cycloserine condition, PL = placebo condition, S = partial-smoking
condition, NS = nonsmoking condition)
n=12 per group (6 male, 6 female) DCS/NS DCS/S PL/NS PL/S
Number of stages completed 8.5 (0.3) 9.0 (0.0) 8.7 (0.2) 8.8 (0.2)
Total number of errors (adjusted for the stages not completed) 24.6 (6.3) 12.4 (2.2) 20.6 (4.7) 17.3 (4.2)
Number of errors in stage 1 (discrimination learning) 0.2 (0.1) 0.4 (0.1) 0.5 (0.2) 0.7 (0.3)
Number of errors in stage 2 (simple reversal learning)* 1.7 (0.2) 1.3 (0.1) 1.5 (0.3) 1.2 (0.1)
Number of errors in stage 3 (new dimension introduced but ignored) 2.3 (1.8) 1.2 (0.2) 2.7 (1.0) 1.0 (0.2)
Number of errors in stage 4 (new dimension still ignored) 0.3 (0.1) 0.6 (0.3) 0.2 (0.1) 0.1 (0.1)
Number of errors in stage 5 (reversal, still ignoring the new dimension)# 1.5 (0.2) 1.0 (0.0) 1.4 (0.2) 1.3 (0.2)
Number of errors in stage 6 (intradimensional set-shift) 0.6 (0.1) 0.5 (0.2) 0.8 (0.2) 0.8 (0.2)
Number of errors in stage 7 (reversal, still ignoring the new dimension) 1.3 (0.2) 1.1 (0.1) 1.4 (0.3) 1.2 (0.1)
Number of errors in stage 8 (extradimensional set-shift) 9.5 (3.3) 4.9 (2.4) 6.2 (2.4) 7.3 (2.6)
Number of errors in stage 9 (reversal, still attending to the new dimension) 1.3 (0.2)††† 1.5 (0.3) 2.1 (0.8)†† 1.8 (0.2)†
Total number of errors prior to extradimensional set-shift (blocks 1–7)# 7.8 (2.0) 6.0 (0.6) 8.5 (1.1) 6.2 (0.5)
Reversal learning (errors in stages 2+5 + 7+9) 5.4 (0.6)††† 4.8 (0.3) 6.5 (0.9)†† 5.5 (0.4)†
Attentional flexibility (errors in stages 6+8) 10.1 (3.3) 5.4 (2.3) 7.0 (2.4) 8.2 (2.6)
Test was performed after the smoking manipulation. Values represent means (±SEM)
† n=11, †† n=10, ††† n=9
*p<0.05; # p<0.055 (main effect of smoking group)
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Fig. 2 a Number of false alarms and b mean response times (log) on
the rapid visual information processing (RVIP) test following partial
smoking (S) or the nonsmoking (NS) manipulations in participants
who underwent the drug (DCS) or the placebo (PL) treatment. *p≤
0.05 (independent t test vs. DCS-S groups), †p<0.05 (main effect of
drug group PL vs. DCS)
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smoking itself did not improve performance, although this
might have been expected given the well-established effect
of nicotine in this test (Wesnes and Warburton 1984). This
lack of effect, however, is likely to stem from the fact that
smoking half of the usual amount of tobacco is insufficient
to produce the beneficial effect on attention. Indeed,
Rezvani et al. (2002) observed that low doses of nicotine
did not affect the number of “hits” in a visual signal
detection test in rats even though they increased percent of
correct rejections. However, under these conditions of low
nicotine dosage, a beneficial effect of DCS in combination
with partial smoking on the number of hits would likely
have been detected, if this particular effect of smoking on
sustained attention involves glutamate activity at NMDA
receptors. There is some discrepancy with the preclinical
literature in that one study investigating the beneficial
action of nicotine in a 5-CSRTT found that the NMDA
antagonist CPP was able to reduce the effect of nicotine on
attentional accuracy (Quarta et al. 2007). It is possible then
that had partial smoking improved attentional accuracy in
our participants that DCS might have attenuated such an
effect. However, our interpretation that glutamate action at
NMDA receptors does not play a major role in this effect of
smoking fits well with two other lines of evidence. Firstly,
preclinical studies employing selective nicotinic ligands
suggest that increases in attentional performance are
primarily mediated by non-α7 receptor subtypes (Blondel
et al. 2000; Grottick and Higgins 2000). Secondly, we
previously found that the enhanced attentional accuracy in
the RVIP test following smoking a whole cigarette was
prevented by a low dose of mecamylamine but not by
memantine (see Jackson et al. 2009 and discussion therein).
Overall then, our results confirm that mechanisms underly-
ing the positive attentional effects of smoking probably do
not involve actions at NMDA receptors. There was some
evidence that DCS slowed performance overall, during the
task of sustained attention, as reaction times were increased.
This effect however was independent of the partial-smoking
manipulation. While this might suggest that DCS can affect
response times, the lack of specific interaction makes it
difficult to interpret in terms of a role for glutamate in the
effects of smoking on speed of processing.
In contrast to the lack of specific effects on other
measures of RVIP performance, DCS interacted with the
partial-smoking manipulation to improve inhibitory control,
as measured by the number of errors on the task. This result
is in line with the observation that low doses of nicotine
dose-dependently increase the percentage of correct rejec-
tions in a visual signal detection test in rats without
affecting the number of hits (Rezvani et al. 2002). It is
unlikely that the reduction in errors was secondary to
slower reaction times as this effect only occurred when
partial smoking and DCS were combined. In addition, the
reduced error rate dissociated from target detection rate,
which did not vary across the experimental conditions.
Recently, it has been suggested that lapses in attention may
contribute toward drug dependence via mechanisms that are
independent of those involved in inhibitory control over
behavior (De Wit, 2008). The results reported here are
consistent with such a suggestion, at least in terms of a role
for glutamate in tobacco dependence.
It is of interest to note here the wealth of evidence for the
role of glutamate in inhibitory control. Administration of
glutamate receptor antagonists such as phencyclidine, dizocil-
pine, or ketamine induces impulsive or premature responding
for food rewards in rats (Sanger and Jackson 1989; Sanger
1992; Higgins et al. 2003) and primates (Jentsch et al. 2000)
or impairs the inhibition of inappropriate responses during
performance of cognitive tests in humans (Krystal et al. 1998;
1999; Morgan et al. 2004). Furthermore, NMDA antagonists
that are selective for receptors containing the NR2B subunit
(traxoprodil, Ro 63-1908) also increase premature responding
in animal studies (Higgins et al. 2003; 2005). Finally, Murphy
et al. (2005) showed that infusions of the competitive NMDA
receptor antagonist CPP, into infralimbic (but not prelimbic)
cortex increased premature responding in rats performing a 5-
CSRTT (this measure may be a parallel of RVIP error rate) and
have consequently suggested that glutamatergic systems
involved in response inhibition are localized to a ventromedial
area of prefrontal cortex. In the light of a great deal of evidence
indicating that antagonists at NMDA receptors impair inhib-
itory control, it is reasonable to conclude that the effect of DCS
in combination with partial smoking reflects an agonist action,
that is, a potentiation of the effect of glutamate, possibly
mediated in the ventromedial prefrontal cortex.
There was no evidence that partial smoking affected
performance on the attentional set-shifting task other than by
reducing the number of reversal errors. Although we have
previously seen smoking-induced impairment in the intra-
dimensional set shift component of this task (Nesic et al. 2011),
those results were obtained after smoking a whole cigarette,
so it is probable that the lack of effect in the present study
was due to the self-administration of a subthreshold dose of
nicotine. Set shifting was also unaltered by DCS alone, or the
combination with partial smoking. So, while ligands acting at
NMDA receptors have been shown to alter perseverative
responding in tests of cognitive flexibility in other popula-
tions (Krystal et al. 1998; Heresco-Levy et al. 2002), we were
unable to detect an effect of DCS in smokers, nor did we see
any potentiation of partial smoking. Given the ability of DCS
to potentiate the effects of limited smoking on other measures
(blood pressure, inhibitory control), this once again empha-
sizes the dissociation in mechanisms underlying the different
cognitive actions of nicotine.
An important issue, which complicates the interpretation of
the present findings, is the baseline difference in the duration of
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smoking abstinence between the two drug groups. Analysis of
covariance was used to try to control for this confounding
effect as well as for the confounding effect of the differential
level of breath CO at baseline (reflecting abstinence duration as
well as the habitual level of smoking) in the two smoking
groups, but this may not have been sufficient. This issue is also
pertinent considering that the state of glutamatergic transmis-
sion may vary depending on the degree of dependence and the
duration of smoking deprivation (see Markou 2008 for a
review), and thus the effects of DCS and/or partial smoking
may differ between individuals in early, compared to those in
more advanced, nicotine withdrawal. Furthermore, as the
mode of action of DCS depends on the dose (Priestley et al.
1995) as well as on endogenous glutamatergic tone (Jackson
2010), a study, which would systematically vary the doses of
DCS as well as of nicotine, while controlling for the duration
of abstinence, is needed to produce dose–response data which
would give more detailed insight into the involvement of
NMDA receptor activation in the subjective and cognitive
effects of smoking. Another problem with the present study is
the relatively small sample size. Although the sample of 12
per group was selected because it has relatively high power
(0.80) to detect medium-sized effects (α=0.25), the inclusion
of the covariates in the analyses has reduced this power.
Future studies with a larger number of participants are needed
to confirm the significance of the present findings.
In summary, the glycine-site partial agonist DCS had
bidirectional effects on subjective ratings in moderately
dependent smokers, depending on whether they were absti-
nent or had partially smoked a cigarette. In combination with
partial smoking, DCS produced a small increase in blood
pressure and improved inhibitory control, but did not affect
attentional accuracy or set shifting. These results are consis-
tent with a role for glutamate in the some of the subjective and
physiological effects of smoking and with a dissociation in
mechanisms underlying the cognitive actions. Considered in
the context of current knowledge about relevant brain
mechanisms, our results point to the actions of DCS being
mediated in the ventromedial prefrontal cortex.
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